



## POINT OF VIEW

### To reduce the current rates of ventilator-associated pneumonia after implementation of the Pneumonia Zero program: This is the challenge<sup>☆</sup>

### Reducir las tasas actuales de neumonía asociada a ventilación mecánica tras la implantación del programa Neumonía *Zero*: este es el reto

L. Lorente

Unidad de Cuidados Intensivos, Hospital Universitario de Canarias, Santa Cruz de Tenerife, Spain

Received 21 October 2019; accepted 22 November 2019  
Available online 25 August 2021



#### Current situation of mechanical ventilator-associated pneumonia

Mechanical ventilator-associated pneumonia (VAP) is related to higher morbidity and mortality rates, and increased costs.<sup>1,2</sup> Therefore, different initiatives and measures have been suggested to prevent it.<sup>1,2</sup> The Pneumonia Zero Project (PZP) implemented back in 2011 reviewed 35 measures to prevent VAP, and proposed a package of 7 mandatory measures and 3 non-mandatory but highly recommended measures.<sup>1</sup> The 7 mandatory measures were: 1) education and training in appropriate airway management; 2) strict hand hygiene with alcohol solutions before airway management; 3) oral hygiene with chlorhexidine (0.12% to 0.2%) every 8 h; 4) control and maintenance of cuff pressure >

20 cmH<sub>2</sub>O before washing the mouth with chlorhexidine every 8 h; 5) avoidance of 0-degree supine positioning, when possible; 6) promoting procedures and protocols to safely avoid or reduce intubation and/or its duration; and 7) avoidance of elective changes of ventilator circuits, humidifiers, and endotracheal tubes. The highly recommended measures were: 1) selective digestive decontamination (SDD) or selective oropharyngeal decontamination (SOD); 2) continuous aspiration of subglottic secretions; and 3) peri-intubation systemic antibiotics in patients with decreased level of consciousness. The PZP reduced the rate of VAP from 9.83 down to 4.34 for every 1000 days on mechanical ventilation.<sup>2</sup> Actually, these rates have remained below 7/1000 days on mechanical ventilation according to annual reports from the National Study on Nosocomial Infections Surveillance (Available online: <http://hws.vhebron.net/envin-helics>).

Almost 10 years after the implementation of the PZP new evidence has come to life on several measures. As a matter of fact, some changes could be made to the PZP to keep reducing the current rates of VAP. Also, several clinical practice guidelines on this regard were published by US scientific societies back in 2014,<sup>3</sup> Latin American societies

<sup>☆</sup> Please cite this article as: Lorente L. Reducir las tasas actuales de neumonía asociada a ventilación mecánica tras la implantación del programa Neumonía *Zero*: este es el reto. *Med Intensiva*. 2021;45:501–505.

E-mail address: [lorentemartin@msn.com](mailto:lorentemartin@msn.com)

**Table 1** Recommendations of the different clinical practice guidelines (CPG) after the Pneumonia Zero Project (PZP) on the measures implemented to prevent ventilator-associated pneumonia proposed by the PZP.

	American guidelines 2014 <sup>7</sup>	European guidelines 2017 <sup>8</sup>	French guidelines 2017 <sup>8</sup>	Argentine guidelines 2018 <sup>9</sup>	Chinese guidelines 2019 <sup>10</sup>
Education and training in appropriate airway management	Yes	Not reviewed	Not reviewed	Yes	Yes
Strict hand hygiene with alcohol solutions before airway management	Yes	Not reviewed	Not reviewed	Yes	Yes
Control and maintenance of cuff pressure > 20 cmH <sub>2</sub> O	Specific III	Not reviewed	Yes	III	IA
Mouth wash with chlorhexidine	Continuous monitoring II	Cannot make recommendation due to the possible mortality risk	Yes	II, but still controversial	IIA
Avoidance of 0-degree supine positioning	III	Not reviewed	Yes	III	IIA
Avoid or reduce intubation and/or its duration	I	Not reviewed	VAP	I	IA
Avoidance of elective changes of ventilator circuits, humidifiers, and endotracheal tubes	I No because it does not reduce VAP	Not reviewed	Minimum sedoanalgesia Avoid	I	IIA-change ventilator circuits on a weekly basis
SDD or SOD	I	SOD better than SDD	SDD	Not suggested	IIB
Continuous aspiration of subglottic secretions	II, but not specific continuous.	Not reviewed	Every 6–8 h	II	IA, but not specific continuous.
Antibiotics in comatose patients	Not reviewed	Not reviewed	Not reviewed	Not suggested	Not reviewed

SDD, selective digestive decontamination; SOD, selective oropharyngeal decontamination.

in 2017,<sup>4</sup> French scientific societies in 2017,<sup>5</sup> Argentine societies in 2018,<sup>6</sup> and Chinese scientific societies back in 2019<sup>7</sup> (Table 1).

## Mandatory requirements to meet the Pneumonia Zero Program

Regarding most mandatory measures of the PZP, there are no new studies suggesting their withdrawal. Also, these are not hard to implement. However, regarding mouth washes with chlorhexidine, several meta-analyses have been published that confirm that these not only reduce VAP,<sup>8</sup> but also increase mortality non-significantly, especially in patients not admitted due to cardiac surgery (Table 2). This possible deleterious effect may be associated with the existence of microaspirations of chlorhexidine that can cause pulmonary damage. After analyzing these meta-analyses, the “Safety projects in critically ill patients” counselling board of the Spanish Ministry of Health, Consumer Affairs, and Social Welfare decided to move it from mandatory to non-mandatory recommendation in a meeting held back in June 2018 (<https://semicyuc.org/2018/07/recomendacion-de-lavado-oral-con-clorhexidina-en-pacientes-ventilaSOD>).

Around this time, a retrospective study including 82 274 patients was published that confirmed a higher mortality risk in a group of 11 133 patients treated with mouth wash with chlorhexidine.<sup>9</sup> Mouth wash with chlorhexidine was associated with a higher mortality rate among the 69 208 patients who were not admitted to the ICU and with a lower mortality rate in the 2847 patients on mechanical ventilation  $\leq 96$  h. However, no differences were reported in the mortality rate of the group of 9316 patients admitted to the ICU without mechanical ventilation or in the group of 903 patients on mechanical ventilation  $>96$  h (still, there was a tendency towards a higher mortality rate with the use of chlorhexidine).

## Highly recommended non-mandatory measures of the Pneumonia Zero Program

Regarding SDD or SOD, a meta-analysis of 6 randomized clinical trials (RCT) and 17 884 patients was published back in 2018. It confirmed a lower in-hospital mortality rate associated with the use of these types of decontamination. As a matter of fact, it was lower with SDD compared to SOD. Regarding the aspiration of subglottic secretions (ASS), a meta-analysis of 20 RCTs and 3544 patients published in 2016 confirmed the lower rate of VAP reported.

Regarding peri-intubation systemic antibiotics in patients with decreased level of consciousness, a review published back in 2017 found 4 studies (2 RCTs and 2 observational studies) including a total of 1507 patients (1240 patients from 1 observational study). In all of them, the rate of VAP dropped significantly.<sup>10</sup> In each study, different antibiotics were administered to different patients (from Glasgow Coma Scale  $\leq 12$  until cardiorespiratory arrest), different antibiotics were used (amoxicillin-clavulanic acid, ampicillin-sulbactam, cefuroxime, ceftriaxone), throughout different durations too (from a single dose to 3-day courses). In a RCT published in 2019, 194 patients with out-of-hospital

cardiac arrests treated with hypothermia (89.6 °F to 93.2 °F for 24 h–36 h) were randomized to receive IV amoxicillin-clavulanic acid (dose of 1 g and 200 mg, respectively every 8 h for 2 days) or placebo. The treatment group had a lower rate of early-onset VAP, but no differences in the 28-day mortality rate were reported.<sup>11</sup> Currently, one ongoing randomized clinical trial (RCT) is studying the administration of a single dose of 2 g of ceftriaxone in patients with Glasgow Coma Scale  $\leq 12$  (NCT02265406). To this date, there is no scientific evidence to say what antibiotics and dose should be used, in what kind of patients or what the duration of these antibiotics should be. However, it seems reasonable to think that amoxicillin-clavulanic acid, cefuroxime or ceftriaxone for 2–3 days in intubated patients with Glasgow Coma Scale  $\leq 8$  should be recommended

## Optional unselected measures in the Pneumonia Zero Project (Table 3)

Regarding the administration of probiotics, a meta-analysis of 8 RCTs and 1083 patients published in 2016 concluded that these were associated with a lower rate of VAP.<sup>12</sup> Currently, the RCT is ongoing (NCT02462590).

Regarding the use of antibiotics via respiratory tract a meta-analysis of 6 RCTs and 1158 patients published in 2018 confirmed a lower rate of VAP. However, no differences in the mortality rate in the ICU setting were reported.<sup>13</sup> In the sub-analysis of the administration of nebulized antibiotics of 3 RCTs and 313 patients a significant drop in the rate of VAP was seen. However, the sub-analysis of the administration of instilled antibiotics of 3 RCTs and 845 patients only found a non-significant reduction of the rate of VAP.

A meta-analysis of 3 RCTs and 543 patients, published back in 2015, concluded that the continuous control and maintenance of cuff pressure was associated with a lower risk of VAP. However, no differences were reported in the duration of mechanical ventilation, the ICU stay or in the mortality rate.<sup>14</sup> Regarding the use of silver-impregnated cuffs, a RCT published in 2008 that included 1509 patients found a lower rate of VAP.<sup>15</sup>

A review published back in 2016 on endotracheal tubes with ultra-thin polyurethane cuffs and VAP found 3 studies and 708 patients (a significant reduction was reported in 2 RCTs and a non-significant reduction in 1 RCT). However, no differences were reported in the duration of mechanical ventilation, the ICU stay or in the mortality rate.<sup>16</sup>

Possibly, the implementation of combined measures may be more effective compared to the implementation of isolated measures. A study found a lower rate of VAP when continuous control and maintenance of cuff pressure or ASS were implemented. Also, the rate of VAP was reduced even further after the implementation of 2 measures combined.<sup>17</sup>

## Plan to reduce the current rates of mechanical ventilator-associated pneumonia

It has been suggested to spare SDD, SOD, and ASS as non-mandatory highly recommended measures following the results of meta-analyses including a large number of patients from RCTs. Also, optional measures like the ones proposed

**Table 2** Meta-analyses conducted after the Pneumonia Zero Project (PZP) on mouth hygiene with chlorhexidine vs placebo.

	VAP	Mortality
Li et al. <sup>18</sup>	10 RCTs and 1269 patients; RR, 0.71 (95%CI, 0.54–0.94). Does not specify cardiac surgery or others	7 RCTs and 11 869 patients; RR, 1.15 (95%CI, 0.98–1.35) Does not specify cardiac surgery or others
Zhang et al. <sup>19</sup>	18 RCTs and 3812 patients; RR, 0.59 (95%CI, 0.50–0.69) Does not specify cardiac surgery or others	Not reviewed
Price et al. <sup>20</sup>	Not reviewed	11 RCTs and 2618 patients; OR, 1.25 (95%CI, 1.05–1.50) Does not specify cardiac surgery or others
Klompas et al. <sup>21</sup>	CS: 3 RCTs and 1868 patients; OR, 0.56 (95%CI, 0.41–0.77). No CS: 13 RCTs and 1762 patients; OR, 0.78 (95%CI, 0.60–1.02). Total: 16 RCTs and 3630 patients; OR, 0.73 (95%CI, 0.58–0.92)	CS: 3 RCTs and 1868 patients; OR, 0.88 (95%CI, 0.25–3.14). No CS: 9 RCTs and 1366 patients; OR, 1.13 (95%CI, 0.99–1.29). Total: 12 RCTs and 3234 patients; OR, 1.13 (95%CI, 0.99–1.28)
Villar et al. <sup>22</sup>	10 RCTs and 7349 patients OR, 0.70 (95%CI, 0.48–1.00). Does not specify cardiac surgery or others	Not reviewed
Hua et al. <sup>23</sup>	18 RCTs and 2451 patients; RR, 0.74 (95%CI, 0.61–0.89) Does not specify cardiac surgery or others	15 RCTs and 2163 patients; RR, 1.09 (95%CI, 0.96–1.23) Does not specify cardiac surgery or others

CS, cardiac surgery; CI, confidence interval; OR, odds ratio; RCT, randomized clinical trial; RR, relative risk; VAP, to prevent mechanical ventilator-associated pneumonia.

**Table 3** Recommendations of the different clinical practice guidelines (CPG) after the Pneumonia Zero Project (PZP) on the measures implemented to prevent ventilator-associated pneumonia not proposed by the PZP.

	American guidelines 2014 <sup>7</sup>	European guidelines 2017 <sup>8</sup>	French guidelines 2017 <sup>8</sup>	Argentine guidelines 2018 <sup>9</sup>	Chinese guidelines 2019 <sup>10</sup>
Probiotics	II	Not reviewed	Avoid	Not suggested	IIB
Antibiotics via respiratory tract	Not reviewed	Not reviewed	Avoid	Not reviewed	Not reviewed
Control and maintenance of cuff pressure	III	Not reviewed	Not reviewed	Not suggested	Verification recommended; does not specify whether continuous or intermittent
Silver cuff	II	Not reviewed	Avoid	Not suggested	IIB
Ultrathin polyurethane cuff	III	Not reviewed	Avoid	Not suggested	Not reviewed

in observational studies or meta-analyses of few patients have been suggested. This group of optional measures would include the administration of peri-intubation systemic antibiotics in patients with decreased level of consciousness (this measure is currently considered non-mandatory but highly recommended by the PZP), mouth wash with chlorhexidine (since June 2018, the ‘‘Safety projects in critically ill patients’’ counselling board of the Spanish Ministry of Health, Consumer Affairs, and Social Welfare decided to move it from mandatory to non-mandatory recommendation), and other measures unforeseen by the PZP (probiotics, antibiotics via respiratory tract, continuous control and maintenance of cuff pressure, silver-impregnated cuffs, endotracheal tubes with ultra-thin polyurethane cuffs).

In ICUs with incidence rates of VAP > 7 episodes per 1000 days on mechanical ventilation—the quality standard proposed by SEMICYUC back in 2017 ([https://www.bing.com/searchPC=WCUG&FORM=WCUGDF&q=indicadoresdecalidad2017.semicyuc\\_spa-1.pdf](https://www.bing.com/searchPC=WCUG&FORM=WCUGDF&q=indicadoresdecalidad2017.semicyuc_spa-1.pdf))—internal audits should be conducted to determine whether measures are being implemented correctly, and whether the plan can be improved. If there is no room for improvement and everything has been corrected, more measures than the ones already implemented should be used. For the sake of efficiency, they should be implemented individually and not combined or at the same time. Either one of the 2 non-mandatory but highly recommended measures could be implemented here (SDD/SOD or ASS). It their primary

goal is not achieved, the other non-mandatory but highly recommended measure could be implemented followed by the gradual implementation of optional measures.

## Conflicts of interest

None reported.

## References

1. Álvarez Lerma F, Sánchez García M, Lorente L, Gordo F, Añón JM, Álvarez J, et al. Sociedad Española de Medicina Intensiva; Sociedad Española de Enfermería Intensiva. Guidelines for the prevention of ventilator-associated pneumonia and their implementation. The Spanish “Zero-VAP” bundle. *Med Intensiva*. 2014;38:226–36.
2. Álvarez-Lerma F, Palomar-Martínez M, Sánchez-García M, Martínez-Alonso M, Álvarez-Rodríguez J, Lorente L, et al. Prevention of ventilator-associated pneumonia: the multimodal approach of the Spanish ICU “Pneumonia Zero” program. *Crit Care Med*. 2018;46:181–8.
3. Klompas M, Branson R, Eichenwald EC, Greene LR, Howell MD, Lee G, et al. Society for Healthcare Epidemiology of America (SHEA). Strategies to prevent ventilator-associated pneumonia in acute care hospitals: 2014 update. *Infect Control Hosp Epidemiol*. 2014;35:915–36.
4. Torres A, Niederman MS, Chastre J, Ewig S, Fernandez-Vandellos P, Hanberger H, et al. International ERS/ESICM/ESCMID/ALAT guidelines for the management of hospital-acquired pneumonia and ventilator-associated pneumonia: Guidelines for the management of hospital-acquired pneumonia (HAP)/ventilator-associated pneumonia (VAP) of the European Respiratory Society (ERS), European Society of Intensive Care Medicine (ESICM), European Society of Clinical Microbiology and Infectious Diseases (ESCMID) and Asociación Latinoamericana del Tórax (ALAT). *Eur Respir J*. 2017;50, pii:1700582.
5. Leone M, Bouadma L, Bouhemad B, Brissaud O, Dauge S, Gibot S, et al. Hospital-acquired pneumonia in ICU. *Anaesth Crit Care Pain Med*. 2018;37:83–98.
6. Cornistein W, Colque AM, Staneloni MI, Monserrat Lloria M, Lares M, González AL, et al. [Pneumonia associated with mechanical ventilation. Update and recommendations inter- Societies SADI-SATI]. *Medicina (B Aires)*. 2018;78:99–106.
7. Shi Y, Huang Y, Zhang TT, Cao B, Wang H, Zhuo C, et al. Chinese guidelines for the diagnosis and treatment of hospital-acquired pneumonia and ventilator-associated pneumonia in adults (2018 Edition). *J Thorac Dis*. 2019;11:2581–616.
8. Cantón-Bulnes MI, Garnacho-Montero J. Oropharyngeal anti-sepsis in the critical patient and in the patient subjected to mechanical ventilation. *Med Intensiva*. 2019;43 Suppl 1:23–30.
9. Deschepper M, Waegeman W, Eeckloo K, Vogelaers D, Blot S. Effects of chlorhexidine gluconate oral care on hospital mortality: a hospital-wide, observational cohort study. *Intensive Care Med*. 2018;44:1017–26.
10. Sirvent JM. Antibiotic prophylaxis against ventilator-associated pneumonia in patients with coma: Where are we now? *Med Intensiva*. 2017;41:248–51.
11. François B, Cariou A, Clere-Jehl R, Dequin PF, Renon-Carron F, Daix T, et al. CRICS-TRIGGERSEP Network and the ANTHARTIC Study Group. Prevention of early ventilator-associated pneumonia after cardiac arrest. *N Engl J Med*. 2019;381:1831–42.
12. Bo L, Li J, Tao T, Bai Y, Ye X, Hotchkiss RS, et al. Probiotics for preventing ventilator-associated pneumonia. *Cochrane Database Syst Rev*. 2014;10:CD009066.
13. Póvoa FCC, Cardinal-Fernandez P, Maia IS, Reboredo MM, Pinheiro BV. Effect of antibiotics administered via the respiratory tract in the prevention of ventilator-associated pneumonia: a systematic review and meta-analysis. *J Crit Care*. 2018;43:240–5.
14. Nseir S, Lorente L, Ferrer M, Rouzé A, Gonzalez O, Bassi GL, et al. Continuous control of tracheal cuff pressure for VAP prevention: a collaborative meta-analysis of individual participant data. *Ann Intensive Care*. 2015;5:43.
15. Kollef MH, Afessa B, Anzueto A, Veremakis C, Kerr KM, Margolis BD, et al. NASCENT Investigation Group. Silver-coated endotracheal tubes and incidence of ventilator-associated pneumonia: the NASCENT randomized trial. *JAMA*. 2008;300:805–13.
16. Blot SI, Rello J, Koulenti D. The value of polyurethane-cuffed endotracheal tubes to reduce microaspiration and intubation-related pneumonia: a systematic review of laboratory and clinical studies. *Crit Care*. 2016;20:203.
17. Lorente L, Lecuona M, Jiménez A, Cabrera J, Mora ML. Subglottic secretion drainage and continuous control of cuff pressure used together save health care costs. *Am J Infect Control*. 2014;42:1101–5.
18. Li J, Xie D, Li A, Yue J. Oral topical decontamination for preventing ventilator-associated pneumonia: a systematic review and meta-analysis of randomized controlled trials. *J Hosp Infect*. 2013;84:283–93.
19. Zhang TT, Tang SS, Fu LJ. The effectiveness of different concentrations of chlorhexidine for prevention of ventilator-associated pneumonia: a meta-analysis. *J Clin Nurs*. 2014;23:1461–75.
20. Price R, MacLennan G, Glen J, SuDDICU Collaboration. Selective digestive or oropharyngeal decontamination and topical oropharyngeal chlorhexidine for prevention of death in general intensive care: systematic review and network meta-analysis. *BMJ*. 2014;348:g2197.
21. Klompas M, Speck K, Howell MD, Greene LR, Berenholtz SM. Reappraisal of routine oral care with chlorhexidine gluconate for patients receiving mechanical ventilation: systematic review and meta-analysis. *JAMA Intern Med*. 2014;174:751–61.
22. Villar CC, Pannuti CM, Nery DM, Morillo CM, Carmona MJ, Romito GA. Effectiveness of intraoral chlorhexidine protocols in the prevention of ventilator-associated pneumonia: meta-analysis and systematic review. *Respir Care*. 2016;61:1245–59.
23. Hua F, Xie H, Worthington HV, Furness S, Zhang Q, Li C. Oral hygiene care for critically ill patients to prevent ventilator-associated pneumonia. *Cochrane Database Syst Rev*. 2016;10:CD008367.